Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study

Autor: T. Kanazawa, K. Kume, Hiroyuki Ohta, Kuniki Amano, Susumu Yamada, Noriko Kuwaba, K. Hatta, K. Amano
Rok vydání: 2017
Předmět:
Male
030204 cardiovascular system & hematology
Carotid Intima-Media Thickness
Gastroenterology
Arthritis
Rheumatoid
Cohort Studies
chemistry.chemical_compound
0302 clinical medicine
Piperidines
Risk Factors
Surveys and Questionnaires
Clinical endpoint
Immunology and Allergy
Single-Blind Method
Prospective cohort study
Ultrasonography
Janus kinase inhibitor
Middle Aged
Intention to Treat Analysis
Up-Regulation
Carotid Arteries
Cholesterol
Rheumatoid arthritis
cardiovascular system
Female
medicine.drug
Adult
medicine.medical_specialty
Immunology
Drug Administration Schedule
03 medical and health sciences
Rheumatology
Internal medicine
medicine
Humans
Pyrroles
cardiovascular diseases
Protein Kinase Inhibitors
Aged
030203 arthritis & rheumatology
Tofacitinib
business.industry
Atherosclerosis
medicine.disease
Methotrexate
Pyrimidines
chemistry
business
Zdroj: Rheumatology International. 37:2079-2085
ISSN: 1437-160X
0172-8172
DOI: 10.1007/s00296-017-3844-9
Popis: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. This study aimed to analyze the effects of Tofacitinib treatment, a Janus kinase inhibitor, on atherosclerosis in patients with RA. Patients with an active RA (28-joint disease activity score–erythrocyte sedimentation rate > 3.2) despite methotrexate (MTX) treatment 12 mg/week were included in this open-label prospective study and started on Tofacitinib (10 mg/day, 5 mg twice/day). Japanese guideline does not allow high dose of MTX. All patients used a stable dosage of MTX, steroids, and statins or lipid-lowering drugs. The primary endpoint was the comparison of the carotid intima-media thickness (CIMT) at the baseline and 54 weeks after Tofa treatment. Clinical data were collected at regular visits. Forty-six patients completed this study. CIMT did not significantly change from baseline to 54 weeks (1.09 ± 0.69 and 1.08 ± 0.78 mm, p = 0.82). In 12 patients who had atherosclerosis at baseline (carotid intima-media thickness > 1.10 mm), there was a significant decrease in CIMT (0.05± 0.026 mm; p
Databáze: OpenAIRE
Externí odkaz: